J&J expects jump in COVID vaccine sales in 2022, eyes device deals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Johnson & Johnson (JNJ) PT Raised to $163 at Goldman Sachs
January 26, 2022 7:36 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Johnson & Johnson (NYSE: JNJ) to $163.00 (from $161.00) while maintaining a Neutral rating.
... More